Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved..
INTRODUCTION: With advances in hepatitis B virus (HBV) therapies, there is a need to identify serum biomarkers that assess the HBV covalently closed circular DNA (cccDNA) reservoir and predict functional cure in HIV/HBV co-infection.
METHODS: In this retrospective study, combining samples from HIV/HBV co-infected participants enrolled in two ACTG interventional trials, proportions achieving HBsAg less than 0.05 log10 IU/ml and HBV RNA less than log10 1.65 U/ml or not detected (LLoQ/NEG) in response to DUAL [tenofovir TDF+emtricitabine (FTC)] vs. MONO [FTC or lamivudine (3TC)] HBV-active ART, were measured. Predictors of qHBsAg less than 0.05 log10 IU/ml were evaluated in logistic regression models.
RESULTS: There were 88 participants [58% women, median age 34; 47 on DUAL vs. 41 on MONO HBV-active ART]. Twenty-one percent achieved HBsAg less than 0.05 log10 IU/ml (30% DUAL vs. 10% MONO). Time to HBsAg less than 0.05 log10 IU/ml was lower (P = 0.02) and the odds of achieving HBsAg less than 0.05 log10 IU/ml were higher (P = 0.07) in DUAL participants. HBV RNA became less than LLoQ/NEG in 47% (DUAL 60% vs. MONO 33%). qHBsAg less than 3 log10 IU/ml was the strongest predictor of HBsAg less than 0.05 log10 IU/ml.
CONCLUSION: This study supports current recommendations of TDF-based DUAL-HBV active ART for initial use in HIV/HBV co-infection. HBV RNA could be a useful marker of treatment response in HIV/HBV co-infected patients on HBV-active ART.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
AIDS (London, England) - 36(2022), 7 vom: 01. Juni, Seite 975-984 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hawkins, Claudia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2T8Q726O95 |
|---|
| Anmerkungen: |
Date Completed 06.06.2022 Date Revised 21.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/QAD.0000000000003193 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336973039 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336973039 | ||
| 003 | DE-627 | ||
| 005 | 20231225233347.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/QAD.0000000000003193 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1123.xml |
| 035 | |a (DE-627)NLM336973039 | ||
| 035 | |a (NLM)35165216 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hawkins, Claudia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.06.2022 | ||
| 500 | |a Date Revised 21.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a INTRODUCTION: With advances in hepatitis B virus (HBV) therapies, there is a need to identify serum biomarkers that assess the HBV covalently closed circular DNA (cccDNA) reservoir and predict functional cure in HIV/HBV co-infection | ||
| 520 | |a METHODS: In this retrospective study, combining samples from HIV/HBV co-infected participants enrolled in two ACTG interventional trials, proportions achieving HBsAg less than 0.05 log10 IU/ml and HBV RNA less than log10 1.65 U/ml or not detected (LLoQ/NEG) in response to DUAL [tenofovir TDF+emtricitabine (FTC)] vs. MONO [FTC or lamivudine (3TC)] HBV-active ART, were measured. Predictors of qHBsAg less than 0.05 log10 IU/ml were evaluated in logistic regression models | ||
| 520 | |a RESULTS: There were 88 participants [58% women, median age 34; 47 on DUAL vs. 41 on MONO HBV-active ART]. Twenty-one percent achieved HBsAg less than 0.05 log10 IU/ml (30% DUAL vs. 10% MONO). Time to HBsAg less than 0.05 log10 IU/ml was lower (P = 0.02) and the odds of achieving HBsAg less than 0.05 log10 IU/ml were higher (P = 0.07) in DUAL participants. HBV RNA became less than LLoQ/NEG in 47% (DUAL 60% vs. MONO 33%). qHBsAg less than 3 log10 IU/ml was the strongest predictor of HBsAg less than 0.05 log10 IU/ml | ||
| 520 | |a CONCLUSION: This study supports current recommendations of TDF-based DUAL-HBV active ART for initial use in HIV/HBV co-infection. HBV RNA could be a useful marker of treatment response in HIV/HBV co-infected patients on HBV-active ART | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Hepatitis B Surface Antigens |2 NLM | |
| 650 | 7 | |a Lamivudine |2 NLM | |
| 650 | 7 | |a 2T8Q726O95 |2 NLM | |
| 650 | 7 | |a RNA |2 NLM | |
| 650 | 7 | |a 63231-63-0 |2 NLM | |
| 650 | 7 | |a Emtricitabine |2 NLM | |
| 650 | 7 | |a G70B4ETF4S |2 NLM | |
| 700 | 1 | |a Kang, Minhee |e verfasserin |4 aut | |
| 700 | 1 | |a Bhattacharya, Debika |e verfasserin |4 aut | |
| 700 | 1 | |a Cloherty, Gavin |e verfasserin |4 aut | |
| 700 | 1 | |a Kuhns, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Matining, Roy |e verfasserin |4 aut | |
| 700 | 1 | |a Thio, Chloe |e verfasserin |4 aut | |
| 700 | 1 | |a Samaneka, Wadzanai |e verfasserin |4 aut | |
| 700 | 1 | |a Chinula, Lameck |e verfasserin |4 aut | |
| 700 | 1 | |a Mulinda, Nyirenda |e verfasserin |4 aut | |
| 700 | 1 | |a Badal-Faesen, Sharlaa |e verfasserin |4 aut | |
| 700 | 1 | |a Sugandhavesa, Patcharaphan |e verfasserin |4 aut | |
| 700 | 1 | |a Lama, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Gaseitsiwe, Simani |e verfasserin |4 aut | |
| 700 | 1 | |a Holzmayer, Vera |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Peters, Marion |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t AIDS (London, England) |d 1988 |g 36(2022), 7 vom: 01. Juni, Seite 975-984 |w (DE-627)NLM012619280 |x 1473-5571 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2022 |g number:7 |g day:01 |g month:06 |g pages:975-984 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/QAD.0000000000003193 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2022 |e 7 |b 01 |c 06 |h 975-984 | ||